• About
    • Team
    • Contact
  • Ophthalmics
  • Investors
    • AGM Notices
    • Financials
    • Research & Development
  • News


Genix Pharmaceuticals Corporation Completes Purchase of Rights to 30 Ophthalmic Generic Drugs and Product Dossiers

Genix Pharmaceuticals Corporation Enters into a Definitive Agreement to Acquire Global Rights to Flu-X(R)

Genix Pharmaceuticals Corporation Announces Non-Brokered Private Placement

Genix Pharmaceuticals Corporation Announces the Extension of Payment Terms for the Acquisitions of Rights to Renochlor®, Sucanon® and Flu-x™

Genix Pharmaceuticals Corporation Announces Closing of Initial Tranche of Over Subscribed Non-Brokered Private Placement

Genix Pharmaceuticals Corporation Announces Closing of Second Tranche Financing and closing of acquisition of rights to Nutraceutical Products Sucanon® and Renochlor®

Genix Pharmaceuticals Corporation Announces AGM Results and Welcomes New Director

Genix Pharmaceuticals Corporation Announces Appointment of New Chief Financial Officer

Genix Pharmaceuticals Corporation prepares to file Abbreviated New Drug Submissions (ANDS) for its first ten Ophthalmic Drugs with Health Canada

Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for Canada’s First Generic Thyroid Medication

1 2 3 Next
Suite 300, 1055 West Hastings St, Vancouver, BC, V6E 2E9
604.609.6198
info@genixpharm.com

LINKS

  • Ophthalmics
  • Investors
  • News

OUR COMPANY

  • About
  • Investors
  • Contact
  • Disclaimers
  • Terms of service

OUR NEWSLETTER

Subscribe to the mailing list to receive updates on new arrivals, special offers and other information


© 2022 Created by Genix Pharmaceuticals